Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK1D | P48730 | 1/20 | 0.42 |
| ▸ | DYRK1A | Q13627 | 5/20 | 0.40 |
| ▸ | WNT1 | P04628 | 3/20 | 0.40 |
| ▸ | FLT3 | P36888 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5817740 | 0.88 | CSNK1D (0.46) | CSNK1DDYRK1AWNT1 | |
| SCHEMBL4179665 | 0.87 | CSNK1D (0.46) | CSNK1DDYRK1AWNT1 | |
| SCHEMBL4085589 | 0.86 | CSNK1D (0.42) | CSNK1DDYRK1AWNT1 | |
| SCHEMBL4083131 | 0.86 | CSNK1D (0.45) | CSNK1DDYRK1AWNT1FLT3 | |
| SCHEMBL13812265 | 0.85 | CSNK1D (0.61) | CSNK1DDYRK1AWNT1 | |
| SCHEMBL4541190 | 0.84 | WNT1 (0.46) | DYRK1AWNT1FLT3 | |
| SCHEMBL13876985 | 0.82 | CSNK1D (0.47) | CSNK1DDYRK1AWNT1 | |
| SCHEMBL4169696 | 0.80 | CSNK1D (0.47) | CSNK1DDYRK1AWNT1 | |
| SCHEMBL4084821 | 0.80 | CSNK1D (0.57) | CSNK1DDYRK1AWNT1 | |
| SCHEMBL4084647 | 0.79 | CLK2 (0.46) | CSNK1DDYRK1AWNT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2065383-A1 | Indazole compounds and methods of use thereof as protein kinase inhibitors | Signal Pharmaceuticals, Inc. (US) | 2009-06-03 | — | — | EP | disclosed |
| US-20090099178-A1 | INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF | BHAGWAT SHRIPAD S | 2009-04-16 | — | — | US | disclosed |
| US-20060004043-A1 | Indazole compounds and methods of use thereof | BHAGWAT SHRIPAD S | 2006-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099178-A1 | INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF | WNT3, WNT3A, WNK3 | CSNK1D 702/4885DYRK1A 461/4885WNT1 4/4885 |
| US-20060004043-A1 | Indazole compounds and methods of use thereof | WNT3, WNT3A, WNK3 | CSNK1D 687/4885DYRK1A 354/4885WNT1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.